Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. - Wikidata - wikimedia - TriplyDB

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

http://www.wikidata.org/entity/Q51373837

about

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib Vascular Complications of Cancer Chemotherapy Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.Novel targeted therapies for eosinophil-associated diseases and allergy An update on cardio-oncology.Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial Clinical cardiac safety profile of nilotinib.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib.High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets Is imatinib still the best choice as first-line oral TKI.Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.Management of the new patient with CML in chronic phase.Chemotherapy-related cardiotoxicity.Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.How I treat newly diagnosed chronic myeloid leukemia in 2015.Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.Chronic myeloid leukemia: Second-line drugs of choice.

P2860

Q26749324-86CE09DB-DBA6-4808-AE3A-30CABFDFE0F6 Q26751285-BE6C4948-4376-4880-B69B-5E98893A5826 Q26766269-D3A71B19-55D7-44A0-8417-515A7FE7648D Q28078946-BC2A686C-56E6-4C66-BC21-EECD2FA7347F Q28079372-8754AB0E-01FD-4269-8C25-77DF5F881879 Q28586705-F483B70E-D2F0-46ED-BA6E-64E5A09E69E1 Q30242015-9E75A8D6-DF81-4340-B329-038581FC8F14 Q30884142-6F41607F-80B9-4BEE-A038-69A6C0090D88 Q33401360-1DE1A80C-6C3D-452A-87A6-DBA6CB242C41 Q33408049-CCF994C5-4F76-4382-9645-9B66EDE09723 Q33419794-1C726438-A8BA-4E93-A522-F855780F62F5 Q33564645-78AEDBD6-E7E1-4FE9-B02C-9FBEB65DE591 Q33828570-0CE5F7C2-4B1C-4B0F-8332-D028622629FD Q34444620-2556562A-8BDF-40F9-9D91-911EF077162F Q34650059-0D0035FF-D80C-4562-857A-354D97258C40 Q35961706-E5D18C3E-EC0C-4440-B51D-88A3B5EB0AFE Q36006389-0A92D46B-19D3-47C9-B4AC-181CEC841E34 Q36316309-DBE44D5E-4C77-4624-B1D1-32F25EA12E13 Q36355098-9408440A-5A7C-42CE-915E-AAE8631EE299 Q36708942-535AFF07-E206-4B83-B229-482E33237CD5 Q36755620-EE2966A1-A9A6-4557-AAF2-8D129F52A3DB Q36891574-6DD41EE5-18DF-49A8-B499-08E9F7AE3E2E Q37026032-012D34F5-774F-4B0F-9D02-32F00887A2E0 Q37209315-7E783F27-6AD3-481A-8B6B-7685AB676281 Q37381574-FF33A4AE-D227-445F-BA13-3C0825C3EFD4 Q37391801-9FC4A238-CA12-4DCF-8BD4-3CE4D64717FA Q37509428-BF303E35-8130-4F61-9AB0-BADF0F01823D Q37654034-5861B016-56B0-4F23-A78A-D70A6B5120D3 Q37999108-90F6B767-D292-4C0A-9CA6-77143593F757 Q38079151-3388FE32-9DC4-4A98-8141-484500F358B5 Q38088974-EFD3B9ED-BC6B-4A41-958D-79D196E4D28C Q38095848-342B5C60-29BF-4FDE-A35B-86710D8C9C9D Q38148243-8C542E04-6C16-4967-ABFC-6310CA10B7C5 Q38265086-6A0AAF84-F9ED-4797-9D2C-CA541FC424CB Q38389475-8D4AD1E7-7001-4005-8F42-01151A7AC941 Q38392679-D0EDF9A8-6197-42B6-A4AC-26BC7C8634D3 Q38404422-5219C6BD-D867-42E1-ABA5-713256964291 Q38457554-44336564-10B0-4D40-B018-35AF50DD54F9 Q38587453-88357371-30D2-463E-A902-B64588D1E05D Q38640422-1F4AC33B-25AE-459B-99B9-244777F49901

P2860

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

http://www.wikidata.org/entity/Q51373837

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Progressive peripheral arteria ...... ring nilotinib therapy in CML.

@en

Progressive peripheral arteria ...... ring nilotinib therapy in CML.

@nl

type

label

Progressive peripheral arteria ...... ring nilotinib therapy in CML.

@en

Progressive peripheral arteria ...... ring nilotinib therapy in CML.

@nl

prefLabel

Progressive peripheral arteria ...... ring nilotinib therapy in CML.

@en

Progressive peripheral arteria ...... ring nilotinib therapy in CML.

@nl

P1433

Q51373837-63A311C4-4FA2-4816-920E-90DCA82DC4DD

P1476

Q51373837-0BB68D6A-13DB-4BCB-9515-F8380E7F5110

P2093

Q51373837-0F1ED207-23F9-409E-B846-62DD3E1FD25D

Q51373837-1400E2FB-FDBE-4B08-8D22-D1C3D4D0F4D0

Q51373837-3DB77C70-79B1-45E1-801B-43E420D2AE7C

Q51373837-764FA482-6114-4285-B33F-6C5EF6036131

Q51373837-A20B7E5C-5102-449B-8B7C-B01C33D77130

Q51373837-A93F458A-844F-4EB9-84BE-2C900B0BB7B0

P2860

Q51373837-066A37BE-6AA6-4DAE-AA81-8F56759CA060

Q51373837-13716117-A00A-45DA-8944-0588C70B45BB

Q51373837-19DFF8A6-7E5E-4C38-946D-283DBAABB0D3

Q51373837-2467296D-56A3-4AEB-AA19-4E18C3CE1A2A

Q51373837-253075FB-7D17-4467-A00F-3342D975FDBF

Q51373837-2AE3D110-84A4-43A6-BAAE-D0F14E91C39C

Q51373837-2F496ABA-D564-472C-A229-8B28CF6F5ECC

Q51373837-37DB2736-D473-4C82-998C-00B2A4A85D1C

Q51373837-380423E7-94AB-4898-B5DA-7B718D49D01A

Q51373837-380E4C89-051E-49A4-8340-18EA0D49773B

P304

Q51373837-0C3BD9F8-A446-459E-BE6B-DFD4F77AFE18

P31

Q51373837-35642740-DD14-4E8A-9167-90F99053D3AB

P356

Q51373837-BC0838FA-D2BA-4C10-A71D-8999278E769F

P433

Q51373837-829AE106-E70A-4E09-B40C-2C2D91E1624E

P478

Q51373837-46D7E50A-BFF4-4869-9F5C-E79FF9B83F06

P50

Q51373837-AC178E03-A19F-4430-B722-38859ABFF218

P577

Q51373837-94E79C44-5EC6-45AC-8D4C-2314F96A21F9

P5875

Q51373837-EE1F88F5-0A6D-479E-8A91-4932FC33E8DC

P698

Q51373837-4B83B924-8C92-4301-A172-F080F8E76219

P356

P1433

American Journal of Hematology

P1476

Progressive peripheral arteria ...... uring nilotinib therapy in CML

@en

P2093

Christian Sillaber

http://www.w3.org/2001/XMLSchema#string

Gerit-Holger Schernthaner

http://www.w3.org/2001/XMLSchema#string

Gerlinde Mitterbauer-Hohendanner

http://www.w3.org/2001/XMLSchema#string

Karl J Aichberger

http://www.w3.org/2001/XMLSchema#string

Martin Schillinger

http://www.w3.org/2001/XMLSchema#string

Susanne Herndlhofer

http://www.w3.org/2001/XMLSchema#string

P2860

Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis

Large and small vessels atherosclerosis: similarities and differences

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice.

The biology of chronic myeloid leukemia.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Imatinib attenuates diabetes-associated atherosclerosis.

P304

533-539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.22037

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51094425

http://www.w3.org/2001/XMLSchema#string

P698

21538470

http://www.w3.org/2001/XMLSchema#string